PF-Atlas › Clinical Trials › NCT03949530
A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis
IDL-2965 Oral Capsule · Phase 1
Registry ID
NCT03949530
Phase
Phase 1
Status
Terminated
Drug / intervention
IDL-2965 Oral Capsule
Sponsor
Indalo Therapeutics, Inc.
Start
2019-04-16
Enrollment
6
Locations
1
About this trial
The purpose of this study is to test the safety and tolerability of the drug candidate IDL-2965 and to see how it is absorbed, processed, and removed by the body.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03949530 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.